INTRODUCTION {#S1}
============

Tandem of pore domains in a weak inward rectifying K^+^ channel (TWIK)-1-related K^+^-channel (TREK-1) is a two-pore domain potassium channel (K2P) expressed throughout the brain and peripheral nervous system ([@R11]). Small to medium sensory neurons in the dorsal root ganglion (DRG) express high levels of TREK-1, and this expression gives rise to a hyperpolarizing background current that works opposite nociceptive channels (e.g., transient receptor potential cation channel subfamily V member 1 \[TRPV1\] channels; [@R1]) to suppress pain ([@R21]). Stretch, swelling, poly-unsaturated fatty acids (PUFAs), volatile anesthetics ([@R10]; [@R18]; [@R25]; [@R27]; [@R28]), and the anionic signaling lipids phosphatidylinositol 4,5-bisphosphate (PIP~2~) and phosphatidic acid (PA) are thought to regulate TREK-1 ([@R5]; [@R8]; [@R23]). In addition to TREK-1, anionic lipids regulate numerous ion channels that control cell membrane potential, permeability, and excitability ([@R15]; [@R17]; [@R33]).

Recently, structural and biochemical studies have shown that anionic signaling lipids directly bind to and gate ion channels ([@R12]; [@R15]; [@R16]; [@R34]; [@R37]). For example, PIP~2~ and PA bind tightly to a lipid binding site located within the transmembrane domain of the inward K^+^ rectifier Kir2.2, gate the channel in a dose-dependent manner, and define the prototypical "lipid gating" of an ion channel ([@R15]; [@R16]). Also, PIP~2~ inhibits TRPV1 by directly binding to a site in the transmembrane domain of the channel ([@R13]). Perturbations of anionic lipids in cell membranes regulate TREK-1 similar to Kir and TRPV1, suggesting lipids may bind directly to a site in TREK-1 ([@R5], [@R6]). Supporting this hypothesis, a recent crystal structure revealed the primary residues that conveyed PIP~2~ sensitivity are in a structured α helix extending from the fourth transmembrane domain (M4) helix ([@R9]) (PDB: 4XDK, D subunit) (see [Figure S1](#SD1){ref-type="supplementary-material"}).

However, which lipids bind and whether they agonize or antagonize the channel remains unclear. PA appears to activate TREK-1 as phospholipase D2 (PLD2) directly binds to TREK-1 and activates the channel through local production of lipid ([@R8]). PIP~2~ regulation of TREK-1 is more complex; initially, PIP~2~ was thought to activate the channel, and G~q~ depletion of PIP~2~ inactivated the channel ([@R19]; [@R23]). But later studies showed increasing PIP~2~ after activation inhibits TREK-1 ([@R6]). To identify lipid ligands and measure the affinities of lipids directly binding to potassium channels, we developed a simple mix-and-read fluorescent lipid binding assay amenable to TREK-1, TWIK-related arachidonic acid activated K^+^ channel (TRAAK), Kir2.1, and Kir2.2 channels. We show that PIP~2~ directly binds to TREK-1 and competes with lipid agonists PA and phosphatidylglycerol (PG) in purified liposomes. These data, combined with previous studies of PLD2 activation of TREK-1 ([@R8]), led us to propose a model where PIP~2~ can directly antagonize TREK-1.

RESULTS {#S2}
=======

Development of a Lipid Binding Assay {#S3}
------------------------------------

To test PIP~2~ binding to TREK-1, we fused a nanoluciferase (Nluc) to the C terminus of the channel and identified a soluble fluorescent PIP~2~ (FL-PIP~2~) analog suitable for binding to TREK-1. [Figure 1A](#F1){ref-type="fig"} shows a cartoon of the assay design. Activation of Nluc produced an FL-PIP~2~-dependent bioluminescence resonance energy transfer (BRET) signal specific to TREK-1 ([Figure 1B](#F1){ref-type="fig"}). When directly titrated, the soluble FL-PIP~2~ probe bound TREK-1 with a dissociation constant (K~d~) of 1.6 μM and a Hill slope of 1.35 ([Figure 1C](#F1){ref-type="fig"}).

In addition to TREK-1, FL-PIP~2~ bound to purified Kir2.2, Kir2.1, and TRAAK channels ([Figure 1B](#F1){ref-type="fig"}). As mentioned, Kir2.2 has known direct binding of PIP~2~ to the transmembrane domain at the cytoplasmic interface ([@R16]). TRAAK is also thought to bind PIP~2~ ([@R10]). Kir2.2 had the highest affinity for PIP~2~ at 120 nM followed by Kir2.1, TREK-1, and TRAAK. As a negative control, we tested FL-PIP~2~ binding to G protein inward-rectifying potassium channel (GIRK/Kir3.2). GIRK is a Kir2 homolog, but only weakly binds PIP~2~ in the absence of G protein (\>30 μM) ([@R37]). As expected, we saw no significant binding of FL-PIP~2~ up to 10 μM ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). The assay also worked using a FRET-based assay with GFP ([Figure S2A](#SD1){ref-type="supplementary-material"}), albeit it required 100 times the protein as the BRET assay (100 nM versus 1.0 nM).

To eliminate the potential artifacts from the luciferase enzyme or the fluorophore attached to the probe, we confirmed PIP~2~ binding to TREK-1 in a radioactive version of the lipid binding assay using a tritiated (^3^H) PIP~2~ and a scintillation proximity assay (SPA). [Figure 1D](#F1){ref-type="fig"} shows binding of ^3^H-PIP~2~ to detergent-purified TREK-1 channel; FL-PIP~2~ dose-dependently competed with ^3^H-PIP~2~ (K~d~, 0.80 μM; Hill slope, −0.85) (see also [Figure S2C](#SD1){ref-type="supplementary-material"}).

Pharmacology of Endogenous Membrane Lipids {#S4}
------------------------------------------

We rapidly screened the binding of endogenous cellular lipids to four potassium channels and identified high-affinity lipid ligands. PA and PIP~2~ bound with varying affinity to TREK-1, TRAAK, Kir2.2, and Kir2.1 ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). We determined a K~d~ for each lipid by fitting the data to a sigmoidal dose-response curve with variable slope (GraphPad Prism). Head group composition drove TREK-1 lipid specificity for both soluble short chain ([Figure S2D](#SD1){ref-type="supplementary-material"}) and native membrane lipids ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). PA and PIP~2~ consistently bound the tightest ([Table S1](#SD1){ref-type="supplementary-material"}). The zwitterionic lipids 8:0 phosphatidylethanolamine (PE) and 8:0 phosphatidylcholine (PC) had no affinity for TREK-1 ([Figure S2C](#SD1){ref-type="supplementary-material"}).

Application of 10 μM arachidonic acid (AA) (free fatty acid) to cells expressing TREK-1 robustly activates TREK-1 ([@R29]). We tested for direct binding of AA to TREK-1 and found both ω-3 and ω-6 AA (free fatty acid) competed with FL-PIP~2~ ([Figure 2C](#F2){ref-type="fig"}). Fatty acid binding was highly specific because eicosapentaenoic acid (EPA, 20:5 ω-3) and saturated fatty acids failed to bind ([Figure 3C](#F3){ref-type="fig"}). The K~d~s for free ω-3 and ω-6 AAs were relatively weak, 67.1 ± 10.8 μM and 73.1 ± 12.1 μM, respectively ([Figure 3D](#F3){ref-type="fig"}; [Table S1](#SD1){ref-type="supplementary-material"}), suggesting phospholipid incorporation into the membrane may also contribute to the activation of TREK-1.

Incorporation of AA into nociceptive membrane directly modulates touch through arachidonyl-containing membrane lipids ([@R36]). If the arachidonyl acyl chains of activating lipids bind directly to the channel, this could increase the affinity and further activate the channel. Using our BRET assay, we found arachidonic-acid-containing PA (AA-PA) (18:0--20:4) bound 2-fold tighter compared with 18:1 PA (9.1 μM versus 15.8 μM; p = 0.0423). AA-PA was also statistically a higher affinity than 16:0--18:1 PA (p = 0.0356). This was not true of arachidonyl PIP~2~ (18:0--20:4) ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}; [Table S1](#SD1){ref-type="supplementary-material"}). Complete removal of an acyl chain had the greater affect. TREK-1 affinity for lyso-PA decreased 3.5-fold compared with diacyl (18:1) PA (56.0 μM versus 15.8 μM) (see also [Table S1](#SD1){ref-type="supplementary-material"}). Shotgun lipidomics of HEK cells treated with 50 μM AA showed an \~10- and 3-fold increase in arachidonyl PG and PA, respectively, further supporting a role for arachidonyl-containing phospholipid in TREK-1 activation ([Figure S4A](#SD1){ref-type="supplementary-material"}).

Lastly, we tested the contribution of the glycerol backbone to TREK-1 affinity. Ceramide-1-phophate (C1P) is often a saturated lipid with an identical head group as PA and differs only in the acyl chain linkage ([Figures S3E--S3G](#SD1){ref-type="supplementary-material"}). We found C1P binding to TREK-1 was 4-fold weaker than PA (79.4 μM versus 19.6 μM; 8:0 and 16:0 lipids were similar). The Hill coefficients were near 1.0 for each lipid. Furthermore, lyso-C1P, i.e., sphingosine-1-phosphate (S1P), had no affinity at 100 μM ([Table S1](#SD1){ref-type="supplementary-material"}). These results suggest the acyl chain and backbone combine to give high-affinity lipid binding in TREK-1. Also, the chemical specificity suggests a structurally well-defined lipid binding site.

Lipid Gating of TREK-1 {#S5}
----------------------

To determine whether PG, PA, and PIP~2~ are TREK-1 agonists or antagonists, we tested ion conductance in a flux assay ([@R2]). PA and PG are both products of the enzyme PLD2 ([@R38]), and we expect these lipids to agonize the channel as PLD2 binds directly to the C terminus of TREK-1 and activates the channel ([@R8]) (see also [Figure S5](#SD1){ref-type="supplementary-material"}). 5--15 mol% PG dose-dependently activated TREK-1 in 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) liposomes, as determined by potassium ion flux ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). PG is relatively abundant in the plasma membrane, and the low affinity is appropriate for agonizing the channel. The flux assay assumes equal incorporation of the channel between lipid types. We confirmed TREK-1 incorporation into the liposome using fluorescence from a GFP tag on TREK-1 ([Figure 3I](#F3){ref-type="fig"}). In PG liposomes, the fluorescence was similar, suggesting the effect of PG on TREK-1 is a lipid-specific interaction. PA likewise activated the channel, albeit with less flux ([Figure 3C](#F3){ref-type="fig"}). Incorporation of TREK-1 appeared to increase with 15 mol% PA compared with 10 mol% (the GFP fluorescence increased to 17,800 RU; p = 0.02, unpaired Student's t test). Hence, some of the increased PA activation may be an artifact of increased TREK-1 incorporation. In contrast with PG and PA, increasing concentrations of PIP~2~ (0.5, 1, and 2 mol%) failed to activate TREK-1: the highest concentration of PIP~2~, 2 mol%, induced the least flux ([Figures 3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}). Given that our soluble binding assay shows that PIP~2~ binds the channel, we reasoned PIP~2~ could bind and antagonize TREK-1.

To determine antagonistic properties of PIP~2~ on TREK-1, we combined increasing concentration of PIP~2~ with 10% PG, a concentration of PG that opens the channel ([Figure 3A](#F3){ref-type="fig"}, blue trace). Consistent with antagonism, TREK-1 currents were completely inhibited in 5 mol% PIP~2~ ([Figure 3C](#F3){ref-type="fig"}), as were channels in 2 mol%. Unexpectedly, sub-saturating PIP~2~ (0.5 mol%) in the presence of 10 mol% PG enhanced TREK-1 activity ([Figures 3G](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}). Reconstitution efficiency of TREK-1 into the liposomes does not account for the increased flux because the incorporation in 0.5 mol% differed from 5 mol% by less than 20% ([Figure 3I](#F3){ref-type="fig"}), but flux increased 7-fold.

To further confirm that the lipid K~d~ arises from the signaling lipid directly binding to structured protein, we mutated residues in the distal end of the M4 helix, a site previously implicated in lipid binding based on electrophysiology experiments ([@R5]). Consistent with direct lipid binding, we found mutating R297 to cysteine completely blocked 500 nM ^3^H-PIP~2~ binding to TREK-1 ([Figure 4A](#F4){ref-type="fig"}). To confirm the functionality of this cysteine mutant, we tested channel conductance in our ion flux assay. To do this, we made a partner double-cysteine mutation, F171C + R297C (cysTREK), to trap the channel in a disulfide bonded or "lipid-bound" (active) conformation when oxidized, analogous to a pair of cys mutants previously characterized in TRAAK channels using whole-cell patch clamp ([@R3]) (see [Figure S1](#SD1){ref-type="supplementary-material"}). Like patch clamp, cysTREK in liposomes rescued flux activity when oxidized; but when the disulfides were reduced, the channel's flux significantly decreased, consistent with low-affinity agonist binding ([Figure 4C](#F4){ref-type="fig"}). We confirmed a 10-fold loss in lipid binding affinity using our BRET assay ([Figure 4B](#F4){ref-type="fig"}).

Lastly, we investigated the ability of TREK-1 small-molecule antagonists norfluoxetine ([@R9]) (NFX), fluphenazine ([@R35]) (FLZ), and thioridazine ([@R35]) (TRZ) to compete with FL-PIP~2~ binding. FLZ bound tightly to TREK-1 with a K~d~ of 6.5 ± 2.0 μM, followed by TRZ of 52.7 ± 5.5 μM, and NFX of 68.2 ± 14.0 μM ([Figure 4D](#F4){ref-type="fig"}). Also, binding was channel specific because PIP~2~ binding to TRAAK was unaffected by TRZ ([Figure S4B](#SD1){ref-type="supplementary-material"}), in agreement with previous studies ([@R35]). Because PIP~2~ appears to antagonize TREK-1, it is unclear whether binding of small molecules is directly competing or if there are multiple conformations that lead to antagonism. Interestingly, FLZ appeared to bind non-competitively because 40% of FL-PIP~2~ remained bound at what appeared to be near-saturating concentrations ([Figure 4D](#F4){ref-type="fig"}).

DISCUSSION {#S6}
==========

Taken together, the nanomolar affinity for PIP~2~, the specificity for the glycerol backbone and acyl chains, and the agonism by anionic lipids (PA or PG) solidify a high-affinity lipid binding site within TREK-1. [Figure 4E](#F4){ref-type="fig"} shows a proposed model for lipid gating in TREK-1. The PIP~2~ affinity for TREK-1 (860 nM) is only slightly weaker than Kir2.1 (450 nM) and suggests that structural determinants like Kir2.2 exist ([@R15]; [@R16]).

We directly measured the functional effect of PIP~2~ on TREK-1 channels in a purified reconstituted system ([Figure 3A](#F3){ref-type="fig"}). The purified system is critical to determining the direct effect of a lipid, because whole cells are confounded by indirect effects of PIP~2~. For example, PIP~2~ can activate PLD2 ([@R24]), which would indirectly agonize TREK-1 through the generation of PA (see [Figure S5A](#SD1){ref-type="supplementary-material"}), yet appear as activation by PIP~2~. The lateral distribution of lipids varies dramatically ([@R31]) in a membrane, and measuring the precise concentration of lipids near a channel is difficult ([@R15]). This limits our ability to correlate the antagonism in our purified system with exact relevant lipid concentrations in a biological membrane. However, crude increases in PIP~2~ concentration after initial activation have been shown to inactivate TREK-1 in cell culture ([@R6]), consistent with our direct PIP~2~ antagonism playing a role in vivo.

The opposite effect of low and high levels of PIP~2~ in the presence of PG ([Figures 3G](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}) may suggest multiple sites for PIP~2~ binding to TREK-1. TREK-1 is a pseudotetramer (dimer of dimer) and could have two distinct lipid binding sites (one agonizing and one antagonizing). If so, agonizing lipids PA and PG could compete with PIP~2~ through an allosteric mechanism at distinct sites. Alternatively, the dimer could have only one PIP~2~ site (two per dimer) and only antagonize when both sites of the dimer are bound. At sub-saturating concentrations, the presence of PIP~2~ would give the appearance of higher anionic lipid concentration but lack a sufficient concentration to occupy both PIP~2~ sites, thus failing to antagonize the channel. This effect resembles Kir, a homotetramer, which is activated when sub-saturating PA is added to agonizing PIP~2~ ([@R7]; [@R15]). At high concentrations, PA competes off PIP~2~ and antagonizes Kir ([@R16]; [@R20]). As mentioned, PIP~2~ could also indirectly activate TREK-1 through the enzyme PLD2. We recently showed PLD2 necessarily translocates to PIP~2~ during activation ([@R30]). These findings combined with Comoglio's model of localization of PLD2 in the activation of TREK-1 ([@R8]) suggest PIP~2~ could indirectly activate TREK-1 through increasing PLD2 activation and production of PA and PG agonists (see [Figure S5A](#SD1){ref-type="supplementary-material"}). This later mode of action assumes PIP~2~ must bind PLD2 with higher affinity than TREK-1, which is not known. A comparison of these two modes of activation is shown in [Figure S5A, (i) and (ii)](#SD1){ref-type="supplementary-material"}. Distinguishing their relative contributions will require further investigation. The expected changes in cellular lipid concentration relative to TREK-1 activity are modeled in [Figure S5B](#SD1){ref-type="supplementary-material"}.

The large selective increase of arachidonyl-PG ([Figure S4A](#SD1){ref-type="supplementary-material"}) with AA treatment may indicate PG-specific regulation of TREK-1. However, the addition of AA to cells can activate TREK-1 in seconds ([@R29]), and our lipidomics study incorporated AA over 15 min. Furthermore, free AA increases TRAAK currents in liposomes ([@R4]). Additional experiments with sufficient temporal resolution are needed to better define the role of free AA in TREK-1 activation.

So why does PIP~2~ antagonize TREK-1 in liposomes when PA and PG are activating? All three lipids are anionic. Inhibition by a cellular feedback mechanism is impossible in our purified (cell-free) liposomes. Rather, a structural or biophysical feature must explain the functional selectivity. Recent crystal structures of TREK-1 and TRAAK suggested that the lipid binding site, i.e., the distal end of the M4 helix^21^, can move toward the membrane in the active conformation ([@R3]; [@R9]; [@R22]) ([Figure S1](#SD1){ref-type="supplementary-material"}). The span of the inositol head group is substantial, 8.1 Å (see PIP~2~ in [Figure S2B](#SD1){ref-type="supplementary-material"}), and could displace the most distal charges by positioning the anionic phosphate \~8 Å away from the membrane ([Figure 4E](#F4){ref-type="fig"}; [Figure S2B](#SD1){ref-type="supplementary-material"}, PIP~2~ chemical structure). This model is consistent with the previous up/down activating models established through double-cysteine mutants of TRAAK ([@R3]). Conceivably, a thinner membrane could allow PIP~2~ to shift up relative to the TREK-1 and allow the lipid binding site to sit closer to the active conformation. Gain-of-function mutations in TRAAK appeared to destabilize the TM4 helix prior to the lipid binding motif ([@R22]), which could also allow the lipid binding motif to associate with the membrane (move up), although the key residues were not visible in the pertinent structures ([@R22]; [@R26]).

We conclude that lipid agonists and antagonists dually and directly contribute to gating of TREK-1 by binding with high affinity to the channel. We also demonstrate a simple mix-and-read fluorescent assay that accurately characterizes lipid specificity and affinities of a lipid bound to an ion channel. The state-dependent selectivity combined with the small requirement for protein make our soluble assay amenable to ultrahigh-throughput drug screening (2--3 million compounds). Our assay could be combined with high-throughput functional screens (200,000--300,000 compounds) ([@R32]), which would allow a complete strategy for screening of ion channel in a purified system using techniques analogous to soluble proteins.

EXPERIMENTAL PROCEDURES {#S7}
=======================

Protein Expression and Purification {#S8}
-----------------------------------

TREK-1, TRAAK, Kir2.1, Kir2.2, or Kir3.2 (GIRK) containing a C-terminal fluorescent protein (either GFP or Nluc) with 103-His tag was expressed in *Pichia* yeast. After cryo-milling, the proteins were extracted in dodecyl-β-D-maltoside (DDM) with protease inhibitors and purified to homogeneity on a cobalt affinity column followed by size exclusion chromatography (SEC). The final SEC buffer contained 20 mM Tris (pH 8.0), 150 mM KCl, 1 mM EDTA, and 2 mM DDM. All proteins were expressed in milligram quantities with a predominant monodispersed peak ([Figure S4C](#SD1){ref-type="supplementary-material"}) corresponding to the expected molecular weight (MW) of an assembled channel with a fluorescent tag in detergent.

BRET Lipid Binding Assay {#S9}
------------------------

The BRET was done in a 384-well plate, with each well having a total of 50 μL of total reaction volume consisting of 1 nM (binding sites) purified ion channel tagged with Nluc, 500 nM BODIPY-TMR phosphatidylinositol 4,5-bisphosphate (FL-PIP~2~) (Echelon Biosciences), various concentrations of competing ligand, and 1:2,000 furimazine (NanoGlo; Promega), the substrate for Nluc, in the SEC buffer with 7 mM DDM final concentration. BRET signal brought about by the binding of FL-PIP~2~ to TREK-1-Nluc and competition with a ligand was calculated by subtracting signal from Nluc-only control enzyme (purified from bacteria) and measured using Envision Multilabel 2104 plate reader (PerkinElmer) set for dual-emission detection (540 nm for Nluc and 574 nm for FL-PIP~2~) and automatic BRET ratio calculation. Nluc control enzyme was purified from BL1 bacteria cells. Although not used here, background fluorescence can be determined using excess non-FL-PIP~2~ (e.g., C8-PIP~2~) rather than the Nluc control enzyme. Data points were fit to a sigmoidal dose-response curve with variable slope using GraphPad Prism. A FRET version of the assay employed a GFP tag rather than an Nluc tag. See also [Figure S2A](#SD1){ref-type="supplementary-material"} and [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Radioactive Lipid Binding Assay {#S10}
-------------------------------

Binding of ^3^H-PIP~2~ to TREK-1 was detected in a SPA (Perkin Elmer). 100 nM TREK-1 binding sites was mixed in 0.6 mg/mL polyvinyltoluene (PVT) anti-mouse SPA beads, 0.8 μg/ml anti-His antibody, SEC buffer with 7 mM DDM, and a signal measured in a scintillation counter.

Potassium Flux Assay {#S11}
--------------------

Lipids of a desired ratio were mixed, dried, rehydrated, sonicated, and solubilized with 3 mM DDM. Proteoliposomes were formed by mixing 1:100 TREK-1/lipids and removal of detergent with BioBeads (150 mM KCl, 20 mM HEPES \[pH 7.4\]). Sonicated proteoliposomes (5 μL) were added to 195 μL of flux assay buffer (150 mM NaCl, 20 mM HEPES \[pH 7.4\], 2 μM 9-amino-6-chloro-2-methoxyacridine \[ACMA\]) in a 96-well plate at 25°C. Flux was initiated by the addition of the protonophore carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) (1 μM final concentration).

Shotgun Lipidomics {#S12}
------------------

HEK293 cells were treated in 10 cm plates with 50 μM AA for 15 min. The cells were scraped and frozen for lipid extraction. The lipids were extracted using a modified Bligh and Dyer procedure ([@R14]) and analyzed by electrospray ionization (ESI) direct infusion analysis ([@R39]).

Statistical Methods {#S13}
-------------------

All statistical calculations were performed in GraphPad Prism v6.0. For the Student's t test, significance was calculated using a two-tailed unpaired parametric test with significance defined as p \< 0.05. For the multiple comparison test, significance was calculated using an ordinary one-way ANOVA and Tukey's multiple comparison test with a single pooled variance.
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======================
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![Soluble FL-PIP~2~ Binding Assay to PIP~2~ Channels\
(A) Cartoon representation showing a single subunit of detergent-purified TREK-1 fused to the bioluminescent protein, Nluc. Excitation of bound FL-PIP~2~ by Nluc produces a BRET-specific signal. A structure of FL-PIP~2~ (right) labeled with BODIPY-TMR (red circle) (542/574 nm).\
(B) Specific binding of FL-PIP~2~ to TREK-1, TRAAK, Kir2.1, and Kir2.2 and competition with 100 μM non-fluorescent 8:0 PIP~2~. No binding was observed for GIRK.\
(C) Binding saturation curve of FL-PIP~2~ to TREK-1 (K~d~, 1.6 μM; Hill slope, 1.4).\
(D) Dose-dependent competition of bound ^3^H-PIP~2~ (200 nM) with FL-PIP~2~ (K~d~, 0.8 μM; Hill slope, −0.9).\
(E) 8:0 PIP~2~ competition FL-PIP~2~ for TREK-1 (K~d~ of 0.9 ± 0.1 μM), TRAAK (1.4 ± 0.3 μM), Kir2.1 (0.8 ± 0.2 μM), and Kir2.2 (0.1 ± 0.1 μM).\
(F) 8:0 PA competes with K~d~ of 19.6 ± 2.9 μM for TREK-1, 8.5 ± 0.6 μM for TRAAK, 20.1 ± 5.6 μM for Kir2.1, and 29.1 ± 5.3 μM for Kir2.2.\
Error bars represent SEM (n = 3--6). See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms897149f1){#F1}

![TREK-1 Pharmacology of Membrane Lipids\
(A) Single-point competition of soluble lipids (100 μM) with FL-PIP~2~ (500 nM) shows specificity for anionic lipids. Phosphatidylinositol (PI), PE, and PC do not compete for FL-PIP~2~ binding.\
(B) TREK-1 competition curves comparing head group specificity of full-length anionic lipids. PIP~2~ binds with the highest affinity (K~d~, 0.87 ± 0.11 μM). K~d~s for 18:0--20:4 PIP~2~ and 18:1--18:1 PIP~2~ are indistinguishable.\
(C) Single-point competition (100 μM) of FL-PIP~2~ comparing cellular lipids with free fatty acids. The diacylglycerols (DAGs), 8:0 and 18:1 DAG, sphingosine-1-phosphate, stearic acid (18:0), inositol triphosphate (IP~3~), and EPA (20:5) fail to compete off FL-PIP~2~.\
\*\*\*p \< 0.0001; \*\*p \< 0.001; \*p \< 0.05, Student's t test. Error bars represent SEM (n = 3--10). See also [Figures S3--S5](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}.](nihms897149f2){#F2}

![TREK-1 Lipid Gating by Anionic Lipids\
Ion flux assays of purified TREK-1 (GFP or Nluc tagged) reconstituted into DOPC proteoliposomes with anionic lipid.\
(A) DOPG (PG) dose-dependently agonizes TREK-1, 15% \> 10% \> 5% (0.81 ± 0.07, 0.43 ± 0.19, 0.16 ± 0.02, respectively, normalized fluorescence). A black arrow indicates the initiation of flux with CCCP. No flux was observed with 25% DOPE (PE) (red trace).\
(B) Comparison of end fluorescence shown in (A).\
(C) DOPA (PA) also agonizes TREK-1 at 15 and 10 mol% (0.43 ± 0.11 and 0.21 ± 0.05, respectively).\
(D) Comparison of end fluorescence shown in (C).\
(E) DOPIP~2~ (PIP~2~) fails to activate TREK-1 (0.5, 1, and 2 mol% tested).\
(F) Comparison of end fluorescence shown in (E).\
(G) Mixtures of PIP~2~ and PG (10%) show 5 mol% PIP~2~ competes with PG to inhibit TREK-1 (0.11 ± 0.08, normalized fluorescence). Low concentration of PIP~2~ in the presence of 10% PG enhanced TREK-1 agonism (orange trace, 0.79 ± 0.04).\
(H) Comparison of end fluorescence shown in (G).\
(I) Fluorescence emission from TREK1 with a GFP tag after reconstitution into proteoliposomes.\
Error bars represent SEM (n = 3--5); no error bar in (I) is a single measurement. \*\*\*p \< 0.0001, \*\*p \< 0.001, \*p \< 0.05, ANOVA-Tukey's multiple comparison test.](nihms897149f3){#F3}

![Characterization of the TREK-1 Lipid Binding Site\
(A) Cysteine mutants of TREK-1 directly block 500 nM PIP~2~ binding. R297 contributes to a known lipid binding site ([@R5]), and mutant R297C/F171C (cysTREK) traps an open conformation when disulfide bonded ([@R3]).\
(B) Titration of mutant TREK-1 with FL-PIP~2~ results in an \~10-fold decrease in FL-PIP~2~ affinity.\
(C) Ion flux assay of cysTREK-1 rescues activation in the absence of lipid binding when oxidized (purple trace), but not when reduced with DTT (orange circles); control vesicles are shown as gray circles.\
(D) Small molecules fluphenazine (FLZ), thioridazine (TRZ), and norfluoxetine (NFX) dose-dependently compete with FL-PIP~2~. FLZ inhibition is incomplete (red arrow and dashed marker) despite a high affinity, K~d~ of 6.5 ± 2.0 μM. Error bars represent SEM (n = 3--6).\
(E) A cartoon showing a proposed model for lipid gating of TREK-1 channels. Anionic lipids PG, PA, and PIP~2~ diffuse laterally in the plasma membrane and bind to the channel (a single subunit of TREK is shown). A lipid binding motif (cyan cylinder) extends from the last transmembrane helix of the M4 helix near the inner leaflet of the plasma membrane. (Left) Binding of PA (or PG) to the lipid binding motif causes the tip of the helix to translocate up, activating the channel. A solid red sphere represents the negatively charged head group phosphate. Purple spheres represent ions in the conduction pathway. (Right) PIP~2~ displaces PA from the lipid binding site. The geometry of the PIP~2~ head group positions the two negatively charged 4′- and 5′-phosphates of PIP~2~ (solid red circles) \~8Å away from the membrane compared with PA (the distance of the inositol ring). With PIP~2~ bound, the helix adopts a conformation favoring a more closed state of the channel. An X indicates a blocked conduction pathway.\
See also [Figures S6 and S7](#SD1){ref-type="supplementary-material"}.](nihms897149f4){#F4}

###### Highlights

-   A soluble fluorescent assay directly measures lipid binding to potassium channels

-   Lipids are direct ligands for two-pore domain potassium channels TREK and TRAAK

-   Phosphatidic acid (PA) and phosphatidylglycerol (PG) agonize TREK-1

-   Phosphatidylinositol 4,5 bisphosphate (PIP~2~) can directly antagonize TREK-1

[^1]: Lead Contact
